# US 2012/0252878 A1 · Use of cathepsin h

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252878 A1
- Document ID: US20120252878A1
- Status: Published application
- Kind: A1
- Application number: 13/391,673
- Filed: 2010-08-27
- Published: 2012-10-04
- Earliest claimed: 2009-08-31
- Assignees: Sanofi
- Inventors: Mathias Gebauer; Martin Michaelis; Danping Ding-Pfennigdorff; Anke M. Schulte; Christiane Metz-Weidmann
- Web page: https://patentgrep.com/patent/US20120252878A1

## CPC

- C12Q 1/37: involving peptidase or proteinase
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/96466: Cysteine endopeptidases (3.4.22)
- G01N 2800/2842: Pain, e.g. neuropathic pain, psychogenic pain
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Present invention concerns the use of Cathepsin H. Other aspects of the invention concern methods for screening pharmaceuticals, for diagnosing pain susceptibility and for the treatment of pain.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A method for identifying or analyzing a compound that modulates neuropathic pain comprising administering a test compound to a Cathepsin H model system, and determining whether the test compound modulates the amount or activity of Cathepsin H or a functional fragment or derivative thereof in the system.

### Claim 19 (depends on 18)

The method of claim 18, wherein the model system heterologously expresses Cathepsin H or a functional fragment or derivative thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the model system is a non-human transgenic animal.

### Claim 21 (depends on 19)

The method of claim 19, wherein the model system is a cell.

### Claim 22 (depends on 18)

The method of claim 18, wherein the model system is a Cathepsin H knock-out.

### Claim 23 (depends on 22)

The method of claim 22, wherein the model system is a non-human Cathepsin H knock-out animal.

### Claim 24 (depends on 22)

The method of claim 22, wherein the model system is a Cathepsin H knock-out cell.

### Claim 25 (depends on 18)

The method of claim 18, wherein the model system comprises Cathepsin H protein or a functional fragment or derivative thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the Cathepsin H protein or functional fragment or derivative thereof is in a cell.

### Claim 27 (depends on 18)

The method of claim 18, wherein the model system comprises two samples, each sample comprising Cathepsin H or a functional fragment or derivative thereof.

### Claim 28 (depends on 27)

The method of claim 27, wherein the administering step comprises contacting one of the two samples with a test compound.

### Claim 29 (depends on 27)

The method of claim 27, wherein the determining step comprises:
a) determining the amount or activity of Cathepsin H or a functional fragment or derivative thereof in the presence of the test compound
b) determining the amount or activity of Cathepsin H or a functional fragment or derivative thereof in the absence of the test compound, and
c) comparing the amount or activity of Cathepsin H or functional fragment or a derivative thereof in the presence of the test compound to the amount or activity of Cathepsin H or functional fragment or a derivative thereof in the absence of the test compound.

### Claim 30

A method for identifying or analyzing a compound that modulates neuropathic pain comprising administering a test compound to a Cathepsin H model system, and determining whether the test compound modulates the amount or activity of a reporter in the system.

### Claim 31 (depends on 30)

The method of claim 30, wherein the model system comprises a cell heterologously expressing a reporter gene operably linked to a Cathepsin H promoter and/or enhancer or a functional fragment thereof.

### Claim 32 (depends on 30)

The method of claim 30, wherein the model system comprises a first cell transfected with a nucleic acid vector comprising a promoter of a Cathepsin H gene or a functional fragment or derivative thereof operably linked to a reporter gene or a functional fragment thereof, and a second cell transfected with a control vector comprising a reporter gene or a functional fragment that is not operably linked to a functional Cathepsin H promoter or a functional fragment or derivative thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the determining step comprises the steps of:
a) determining the reporter gene activity of the first and second cells in the presence of the test compound, and
b) determining the reporter gene activity of the first and second cells in the absence of the test compound.

### Claim 34 (depends on 30)

The method of claim 30, wherein the model system comprises a nucleic acid coding for a Cathepsin H protein or a functional fragment or derivative thereof in a transcriptionally active system.

### Claim 35 (depends on 34)

The method of claim 34, wherein the determining step comprises the steps of:
a) determining the amount of mRNA coding for the Cathepsin H protein or functional fragment or derivative thereof present in the system in the presence of the test compound, and
b) determining whether the test compound modulates the amount of mRNA coding for the Cathepsin H protein or functional fragment or derivative present in the system.

### Claim 36

A method for identifying or analyzing a compound that modulates neuropathic pain comprising:
a) selecting a compound that modulates the amount or activity of Cathepsin H or a functional fragment or derivative thereof, and
b) administering the compound to a subject experiencing pain in order to determine whether the pain is modulated.

### Claim 37

A method for identifying or analyzing a compound that modulates neuropathic pain in a subject comprising:
a) assaying a biological activity of Cathepsin H or a functional fragment or derivative thereof in the presence of one or more test compounds in order to identify one or more modulating compounds that modulate the biological activity of Cathepsin H or functional fragment or derivative thereof, and
b) testing the one or more modulating compounds for their ability to reduce pain, pain sensation, or pain sensitivity in a subject.

### Claim 38

A model system of neuropathic pain sensitivity that is based upon Cathepsin H expression.

### Claim 39 (depends on 38)

The model system of claim 38, wherein the model system is a model system of enhanced neuropathic pain sensitivity.

### Claim 40 (depends on 39)

The model system of claim 39, wherein the model system comprises a non-human transgenic animal heterologously expressing Cathepsin H or a functional fragment or derivative thereof.

### Claim 41 (depends on 39)

The model system of claim 39, wherein the model system comprises a cell heterologously expressing Cathepsin H or a functional fragment or derivative thereof.

### Claim 42 (depends on 38)

The model system of claim 38, wherein the model system is a model system of lowered neuropathic pain sensitivity.

### Claim 43 (depends on 42)

The model system of claim 42, wherein the model system is a non-human Cathepsin H knock-out animal.

### Claim 44 (depends on 42)

The model system of claim 42, wherein the model system is a Cathepsin H knock-out cell.
